However, only a few P2Y6 antagonists have been developed and evaluated, primarily in vitro or in mice, on medical conditions such as obesity, type 2 diabetes or cardiac fibrosis53–56. This evidence concerns the gene P2RY6 and obesity due to melanocortin 4 receptor deficiency.